The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 5, 2014, Pages

  Nolan, Stephanie ^a   Arnason, Thomas ^a   Drucker, Arik ^b   Huang, Weei Yuarn ^a  

^a Department of Laboratory Medicine Division of Anatomical Pathology ^*  (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

BRAF; Colon cancer; Lynch syndrome; Microsatellite instability; V600E

Indexed keywords

B RAF KINASE; ENZYME ANTIBODY; EOSIN; HEMATOXYLIN; BRAF PROTEIN, HUMAN; EPITOPE;

ACCURACY; ARTICLE; CELL DIFFERENTIATION; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; FALSE NEGATIVE RESULT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; ALGORITHM; CANCER STAGING; CARCINOMA; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPARATIVE STUDY; FEASIBILITY STUDY; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; MUTATION; PATHOLOGY; REPRODUCIBILITY;

ALGORITHMS; CARCINOMA; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; EPITOPES; FALSE NEGATIVE REACTIONS; FEASIBILITY STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 84900401528     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000026     Document Type: Article

References (23)

1. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352: 1851-1860.
2. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999; 36: 801-818.
3. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a lowcost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004; 41: 664-668.
4. Rizzo S, Bronte G, Fanale D, et al. Prognostic vs. predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev. 2010; 36(suppl 3): S56-S61.
5. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-5712.
6. Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti- EGFR therapy in colorectal cancer. J Gastrointest Oncol. 2013; 4: 308-318.
7. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005; 24: 3995-3998.
8. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122: 11-19.
9. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012; 36: 844-850.
10. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012; 36: 1796-1800.
11. Capper D, Voigt A, Bozukova G, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2013; 133: 1624-1630.
12. Affolter K, Samowitz W, Tripp S, et al. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer. 2013; 52: 748-752.
13. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013; 119: 2765-2770.
14. Toon CW, Walsh MD, Chou A, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 2013; 37: 1592-1602.
15. Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch. 2013; 463: 613-621.
16. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013; 63: 187-193.
17. MacQuarrie E, Arnason T, Gruchy J, et al. Microsatellite instability status does not predict total lymph node or negative lymph node retrieval in stage III colon cancer. Hum Pathol. 2012; 43: 1258-1264.
18. Rosenbaum E, Hosler G, Zahurak M, et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol. 2005; 18: 898-902.
19. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65: 6063-6069.
20. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer. 2007; 6: 301-310.
21. Bouzourene H, Taminelli L, Chaubert P, et al. A cost-effective algorithm for hereditary nonpolyposis colorectal cancer detection. Am J Clin Pathol. 2006; 125: 823-831.
22. Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? J Clin Oncol. 2012; 30: 1024-1027.
23. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013; 31: 3997-4013.